Skip to main
APLS
APLS logo

Apellis Pharma (APLS) Stock Forecast & Price Target

Apellis Pharma (APLS) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 29%
Hold 47%
Sell 0%
Strong Sell 6%

Bulls say

Apellis Pharmaceuticals Inc. demonstrated a solid growth trajectory, with total injections increasing by 6% quarter-over-quarter and projected low to mid-single-digit growth for the remainder of the year, indicating a stable demand for its products. The company anticipates accelerated growth in the long term driven by market expansion efforts, including direct-to-consumer campaigns, referral programs, and educational initiatives aimed at healthcare practitioners, particularly in light of recent positive tissue preservation data updates. Additionally, financial updates reflect an increased revenue forecast for Empaveli by approximately 9 to 10% due to recent approvals, alongside reduced projected R&D expenses, thereby highlighting improved financial efficiency and revenue potential.

Bears say

Apellis Pharmaceuticals faces significant commercial risks that could adversely affect its financial outlook, including potential setbacks from increased competition, such as Izervay, and the uncertainty surrounding the launch of its C3G treatment, which may be less common than anticipated. Additionally, financial analysts note that the company's growth projections for geographic atrophy (GA) are lower than those from competitors, raising concerns about market share and acceptance, particularly in relation to existing treatments like Soliris and Ultomiris. Lastly, the risk of adverse clinical outcomes, such as reported instances of retinal vasculitis, poses further threats to the commercial viability and future revenues of Apellis's products.

Apellis Pharma (APLS) has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 29% recommend Buy, 47% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apellis Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apellis Pharma (APLS) Forecast

Analysts have given Apellis Pharma (APLS) a Hold based on their latest research and market trends.

According to 17 analysts, Apellis Pharma (APLS) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apellis Pharma (APLS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.